Source comparison
MK-677 Bone Density Osteoporosis: Treatment Comparison
The table below contrasts MK-677 with standard pharmaceutical osteoporosis interventions based on mechanism, typical BMD outcomes, timeline, and clinical status. MK-677 (25mg daily) Ghrelin receptor agonist → GH/IGF-1 secretion → osteoblast activation 1.8–3.1%
This comparison does not assign a generated winner or score.
- The table below contrasts MK-677 with standard pharmaceutical osteoporosis interventions based on mechanism, typical BMD outcomes, timeline, and clinical status.
- MK-677 (25mg daily)
- Ghrelin receptor agonist → GH/IGF-1 secretion → osteoblast activation
- 1.8–3.1% (trabecular bone, elderly subjects)
- Yes. Restores GH/IGF-1 to mid-normal range
- Investigational only (not FDA-approved for osteoporosis)
- Effective in elderly with baseline GH deficiency; no approval pathway yet; research-grade only
- Bisphosphonates (alendronate 70mg weekly)
- Osteoclast inhibition → reduced bone resorption
- 4–6% (lumbar spine), 2–3% (hip)
- No. Slows breakdown without addressing formation
- FDA-approved (first-line therapy)
- Gold standard for postmenopausal osteoporosis; does not correct hormonal cause
- Teriparatide (PTH 1-34, 20mcg daily SQ)
- PTH analog → direct osteoblast stimulation
- 8–10% (lumbar spine), 3–4% (hip)
- Partially. Mimics anabolic signal but doesn't restore endogenous GH
- FDA-approved (anabolic agent)
- Most potent anabolic; limited to 2 years max use due to theoretical osteosarcoma risk
- Denosumab (60mg SQ every 6 months)
- RANKL inhibitor → osteoclast suppression
- 5–7% (lumbar spine), 3–5% (hip)
- No. Antiresorptive mechanism
- FDA-approved
- Rapid BMD gains; rebound fracture risk upon discontinuation
- Calcium + Vitamin D alone
- Substrate provision for mineralization
- 0–1% (minimal effect on BMD)
- No
- OTC supplement (not regulated as drug)
- Necessary but insufficient. Cannot reverse established osteoporosis alone